Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia.

Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS.

Cancer Immunol Res. 2019 Sep 17. pii: canimm.0152.2019. doi: 10.1158/2326-6066.CIR-19-0152. [Epub ahead of print]

PMID:
31530560
2.

The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors.

Bayraktar R, Bertilaccio MTS, Calin GA.

Front Immunol. 2019 May 14;10:1053. doi: 10.3389/fimmu.2019.01053. eCollection 2019. Review.

3.

IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.

Riva F, Ponzoni M, Supino D, Bertilaccio MTS, Polentarutti N, Massara M, Pasqualini F, Carriero R, Innocenzi A, Anselmo A, Veliz-Rodriguez T, Simonetti G, Anders HJ, Caligaris-Cappio F, Mantovani A, Muzio M, Garlanda C.

Cancer Immunol Res. 2019 Jun;7(6):874-885. doi: 10.1158/2326-6066.CIR-18-0698. Epub 2019 Apr 24.

PMID:
31018956
4.

The involvement of microRNA in the pathogenesis of Richter syndrome.

Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson PA, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA.

Haematologica. 2019 May;104(5):1004-1015. doi: 10.3324/haematol.2018.203828. Epub 2018 Nov 8.

5.

In Vitro Assay to Study CLL and Monocyte Interactions.

Bertilaccio MTS, Zhang R, Banerjee P, Gandhi V.

Methods Mol Biol. 2019;1881:113-119. doi: 10.1007/978-1-4939-8876-1_9.

PMID:
30350201
6.

A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.

Farinello D, Wozińska M, Lenti E, Genovese L, Bianchessi S, Migliori E, Sacchetti N, di Lillo A, Bertilaccio MTS, de Lalla C, Valsecchi R, Gleave SB, Lligé D, Scielzo C, Mauri L, Ciampa MG, Scarfò L, Bernardi R, Lazarevic D, Gonzalez-Farre B, Bongiovanni L, Campo E, Cerutti A, Ponzoni M, Pattini L, Caligaris-Cappio F, Ghia P, Brendolan A.

Nat Commun. 2018 May 3;9(1):1787. doi: 10.1038/s41467-018-04150-7.

7.

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C.

Blood. 2017 Jun 29;129(26):3440-3451. doi: 10.1182/blood-2016-11-751065. Epub 2017 May 2.

8.

Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.

Bordini J, Galvan S, Ponzoni M, Bertilaccio MT, Chesi M, Bergsagel PL, Camaschella C, Campanella A.

Leukemia. 2017 Apr;31(4):967-970. doi: 10.1038/leu.2016.346. Epub 2016 Nov 24. No abstract available.

PMID:
27881873
9.

B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Galletti G, Caligaris-Cappio F, Bertilaccio MT.

Leukemia. 2016 Dec;30(12):2293-2301. doi: 10.1038/leu.2016.261. Epub 2016 Sep 28. Review.

PMID:
27677742
10.

Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.

Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfò L, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, Ghia P, Corti A.

Oncotarget. 2016 Jul 5;7(27):41725-41736. doi: 10.18632/oncotarget.9407.

11.

Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, Ranghetti P, Scarfò L, Ponzoni M, Rocchi M, Corti A, Anselmo A, van Rooijen N, Klein C, Ries CH, Ghia P, De Palma M, Caligaris-Cappio F, Bertilaccio MTS.

Cell Rep. 2016 Feb 23;14(7):1748-1760. doi: 10.1016/j.celrep.2016.01.042. Epub 2016 Feb 11.

12.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

13.

HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, Scarfò L, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, Ghia P, Tonon G, Ponzoni M, Caligaris-Cappio F, Bernardi R.

Blood. 2016 Apr 21;127(16):1987-97. doi: 10.1182/blood-2015-07-657056. Epub 2016 Jan 29.

14.

Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C.

PLoS One. 2015 Jul 29;10(7):e0134748. doi: 10.1371/journal.pone.0134748. eCollection 2015. No abstract available.

15.

Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C.

PLoS One. 2015 Jun 25;10(6):e0130195. doi: 10.1371/journal.pone.0130195. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0134748.

16.

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.

Bordini J, Bertilaccio MT, Ponzoni M, Fermo I, Chesi M, Bergsagel PL, Camaschella C, Campanella A.

Haematologica. 2015 Jun;100(6):834-841. doi: 10.3324/haematol.2014.118000. Epub 2015 Feb 24.

17.

From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia.

Apollonio B, Bertilaccio MT, Restuccia U, Ranghetti P, Barbaglio F, Ghia P, Caligaris-Cappio F, Scielzo C.

J Vis Exp. 2014 Oct 19;(92):e51942. doi: 10.3791/51942.

18.

Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

Simonetti G, Bertilaccio MT, Ghia P, Klein U.

Blood. 2014 Aug 14;124(7):1010-9. doi: 10.1182/blood-2014-05-577122. Epub 2014 Jul 8.

19.

SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.

Simonetti G, Bertilaccio MT, Rodriguez TV, Apollonio B, Dagklis A, Rocchi M, Innocenzi A, Casola S, Winkler TH, Nitschke L, Ponzoni M, Caligaris-Cappio F, Ghia P.

Haematologica. 2014 Aug;99(8):1356-64. doi: 10.3324/haematol.2013.100230. Epub 2014 May 23.

20.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G.

Nat Med. 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. Epub 2014 May 11.

21.

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

Martins LR, Lúcio P, Melão A, Antunes I, Cardoso BA, Stansfield R, Bertilaccio MT, Ghia P, Drygin D, Silva MG, Barata JT.

Leukemia. 2014 Jan;28(1):179-82. doi: 10.1038/leu.2013.232. Epub 2013 Aug 8. No abstract available.

PMID:
23925046
22.

How the microenvironment wires the natural history of chronic lymphocytic leukemia.

Caligaris-Cappio F, Bertilaccio MT, Scielzo C.

Semin Cancer Biol. 2014 Feb;24:43-8. doi: 10.1016/j.semcancer.2013.06.010. Epub 2013 Jul 2. Review.

PMID:
23831274
23.

Targeting B-cell anergy in chronic lymphocytic leukemia.

Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, Scarfò L, Ranghetti P, Stevenson F, Packham G, Ghia P, Muzio M, Caligaris-Cappio F.

Blood. 2013 May 9;121(19):3879-88, S1-8. doi: 10.1182/blood-2012-12-474718. Epub 2013 Mar 4.

24.

Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

ten Hacken E, Scielzo C, Bertilaccio MT, Scarfò L, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M, Ghia P, Caligaris-Cappio F.

Blood. 2013 Mar 21;121(12):2264-73. doi: 10.1182/blood-2012-09-457119. Epub 2013 Jan 16.

25.

Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.

Bertilaccio MT, Scielzo C, Simonetti G, Ten Hacken E, Apollonio B, Ghia P, Caligaris-Cappio F.

Leukemia. 2013 Mar;27(3):534-40. doi: 10.1038/leu.2012.268. Epub 2012 Sep 13. Review.

PMID:
23041721
26.

Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models.

Bertilaccio MT, Simonetti G, Dagklis A, Rocchi M, Rodriguez TV, Apollonio B, Mantovani A, Ponzoni M, Ghia P, Garlanda C, Caligaris-Cappio F, Muzio M.

Blood. 2011 Jul 21;118(3):660-9. doi: 10.1182/blood-2011-01-329870. Epub 2011 Jun 7. Erratum in: Blood. 2012 Sep 27;120(13):2773.

27.

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, Agostoni V, Parma M, Ponzoni M, Bertilaccio MT, Ghia P, Biondi A, Dotti G, Biagi E.

Blood. 2011 May 5;117(18):4736-45. doi: 10.1182/blood-2010-10-311845. Epub 2011 Mar 15.

28.

Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals.

Fazi C, Dagklis A, Cottini F, Scarfò L, Bertilaccio MT, Finazzi R, Memoli M, Ghia P.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S61-8. doi: 10.1002/cyto.b.20545.

29.

How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection.

Scielzo C, Ten Hacken E, Bertilaccio MT, Muzio M, Calissano C, Ghia P, Caligaris-Cappio F.

Leuk Lymphoma. 2010 Aug;51(8):1371-4. doi: 10.3109/10428194.2010.505061.

PMID:
20687794
30.

An overview of chronic lymphocytic leukaemia biology.

Bertilaccio MT, Scielzo C, Muzio M, Caligaris-Cappio F.

Best Pract Res Clin Haematol. 2010 Mar;23(1):21-32. doi: 10.1016/j.beha.2009.12.005. Review.

PMID:
20620968
31.

HS1 has a central role in the trafficking and homing of leukemic B cells.

Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C, Muzio M, Caiolfa V, Kitamura D, Restuccia U, Bachi A, Rocchi M, Ponzoni M, Ghia P, Caligaris-Cappio F.

Blood. 2010 Nov 4;116(18):3537-46. doi: 10.1182/blood-2009-12-258814. Epub 2010 Jun 8.

32.

A novel Rag2-/-gammac-/--xenograft model of human CLL.

Bertilaccio MT, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, Scarfò L, Rocchi M, Muzio M, Caligaris-Cappio F, Ghia P.

Blood. 2010 Feb 25;115(8):1605-9. doi: 10.1182/blood-2009-05-223586. Epub 2009 Dec 16.

33.

The role of toll-like receptors in chronic B-cell malignancies.

Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F.

Leuk Lymphoma. 2009 Oct;50(10):1573-80. doi: 10.1080/10428190903115410. Review.

PMID:
19672768
34.

Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and {beta}2 integrin-dependent cell clearance program.

Maugeri N, Rovere-Querini P, Evangelista V, Covino C, Capobianco A, Bertilaccio MT, Piccoli A, Totani L, Cianflone D, Maseri A, Manfredi AA.

Blood. 2009 May 21;113(21):5254-65. doi: 10.1182/blood-2008-09-180794. Epub 2009 Mar 4.

35.

Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.

Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F.

Br J Haematol. 2009 Feb;144(4):507-16. doi: 10.1111/j.1365-2141.2008.07475.x. Epub 2008 Nov 19.

PMID:
19036098
36.

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, Greenberg NM, Corti A, Bellone M.

Prostate. 2008 Jul 1;68(10):1105-15. doi: 10.1002/pros.20775.

PMID:
18437689
37.

Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.

Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MT, Hess-Michelini R, Doglioni C, Bellone M.

Cancer Res. 2008 Jan 1;68(1):292-300. doi: 10.1158/0008-5472.CAN-07-2429.

38.

Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses.

Iezzi G, Boni A, Degl'Innocenti E, Grioni M, Bertilaccio MT, Bellone M.

J Immunol. 2006 Aug 15;177(4):2131-7.

39.

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration.

Casati A, Zimmermann VS, Benigni F, Bertilaccio MT, Bellone M, Mondino A.

J Immunol. 2005 Mar 15;174(6):3317-25.

40.

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.

Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M.

Eur J Immunol. 2005 Jan;35(1):66-75.

41.

Modulation of human endothelial cell behaviour in simulated microgravity.

Carlsson SI, Bertilaccio MT, Ascari I, Bradamante S, Maier JA.

J Gravit Physiol. 2002 Jul;9(1):P273-4.

PMID:
15002577
42.

Endothelial stress by gravitational unloading: effects on cell growth and cytoskeletal organization.

Carlsson SI, Bertilaccio MT, Ballabio E, Maier JA.

Biochim Biophys Acta. 2003 Oct 21;1642(3):173-9.

Supplemental Content

Loading ...
Support Center